Paraneoplastic Autoantibody CSF Evaluation Algorithm

**Immunofluorescence Assay (IFA)**
- Antineuronal nuclear antibody-type 1 (ANNA-1)
- Antineuronal nuclear antibody-type 2 (ANNA-2)
- Antineuronal nuclear antibody-type 3 (ANNA-3)
- Anti-glial/neuronal nuclear antibody-type 1 (AGNA-1)
- Purkinje cell cytoplasmic antibody-type 1 (PCA-1)
- Purkinje cell cytoplasmic antibody-type 2 (PCA-2)
- Purkinje cell cytoplasmic antibody-type Tr (PCA-Tr)
- Collapsin response-mediator protein-5 Neuronal (CRMP-5, IgG)

**PAC1 / Paraneoplastic Autoantibody Evaluation, Spinal Fluid**
The following tests are always performed:
- Antineuronal nuclear antibody-type 1 (ANNA-1)
- Antineuronal nuclear antibody-type 2 (ANNA-2)
- Antineuronal nuclear antibody-type 3 (ANNA-3)
- Anti-glial/neuronal nuclear antibody-type 1 (AGNA-1)
- Purkinje cell cytoplasmic antibody-type 1 (PCA-1)
- Purkinje cell cytoplasmic antibody-type 2 (PCA-2)
- Purkinje cell cytoplasmic antibody-type Tr (PCA-Tr)
- Collapsin response-mediator protein-5 Neuronal (CRMP-5, IgG)

**IF**: Immunofluorescence

- Neurofilament antibody
  - ANNA-1 antibody by immunoblot
  - ANNA-2 antibody by immunoblot
  - AGNA-1 antibody by immunoblot
  - CRMP-5-IgG Western blot
  - mGluR1 antibody by CBA
  - mGluR1 antibody by IF titer assay
  - AMPA-R antibody by CBA
  - AMPA-R antibody by IF titer assay
  - GABA-B-R antibody by CBA
  - GABA-B-R antibody by IF titer assay
  - PCA-1 antibody by immunoblot
  - PCA-1 antibody by CBA
  - PCA-Tr antibody by immunoblot
  - PCA-Tr antibody by CBA
  - NMDA-receptor antibody by CBA
  - NMDA-receptor antibody by IF titer assay
  - Glutamic acid decarboxylase (GAD65) antibody assay
  - Glutamic acid decarboxylase (GAD65) antibody assay
  - Neuronal voltage-gated potassium channel-complex autoantibody

- Contactin-associated protein-like-2 (CASPR2)-IgG
- Leucine-rich glioma inactivated protein-1 IgG

If neuronal voltage-gated potassium channel-complex autoantibody is ≥0.01 nmol/L